AJP - Lung Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol 277: L628-L635, 1999;
1040-0605/99 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strandjord, T. P.
Right arrow Articles by Sage, E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strandjord, T. P.
Right arrow Articles by Sage, E. H.
Vol. 277, Issue 3, L628-L635, September 1999

Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis

Thomas P. Strandjord1, David K. Madtes2, Daniel J. Weiss2, and E. Helene Sage3

1 Department of Pediatrics, University of Washington, Seattle 98195-6320; 2 Fred Hutchinson Cancer Research Center, Seattle 98109; and 3 Hope Heart Institute, Seattle, Washington 98122

Secreted protein acidic and rich in cysteine (SPARC) has been shown to be coexpressed with type I collagen in tissues undergoing remodeling and wound repair. We speculated that SPARC is required for the accumulation of collagen in lung injury and that its absence would attenuate collagen accumulation. Accordingly, we have assessed levels of collagen in SPARC-null mice in an intratracheal bleomycin-injury model of pulmonary fibrosis. Eight- to ten-week-old SPARC-null and wild-type (WT) mice received bleomycin (0.0035 U/g) or saline intratracheally and were subsequently killed after 14 days. Relative levels of SPARC mRNA were increased 2.7-fold (P < 0.001) in bleomycin-treated WT lungs in comparison with saline-treated lungs. Protein from bleomycin-treated WT lung contained significantly more hydroxyproline (191.9 µg/lung) than protein from either bleomycin-treated SPARC-null lungs or saline-treated WT and SPARC-null lungs (147.4 µg/lung, 125.4 µg/lung, and 113.0 µg/lung, respectively; P < 0.03). These results indicate that SPARC is increased in response to lung injury and that accumulation of collagen, as indicated by hydroxyproline content, is attenuated in the absence of SPARC. The properties of SPARC as a matricellular protein associated with cell proliferation and matrix turnover are consistent with its participation in the development of pulmonary fibrosis.

secreted protein acidic and rich in cysteine; fibroblast; osteonectin; BM-40; lung injury; immunohistochemistry; extracellular matrix


This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
A. Pardo, V. Ruiz, J. L. Arreola, R. Ramirez, J. Cisneros-Lira, M. Gaxiola, R. Barrios, S. V. Kala, M. W. Lieberman, and M. Selman
Bleomycin-induced Pulmonary Fibrosis Is Attenuated in {gamma}-Glutamyl Transpeptidase-Deficient Mice
Am. J. Respir. Crit. Care Med., March 15, 2003; 167(6): 925 - 932.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
R. C. Savani, Z. Zhou, E. Arguiri, S. Wang, D. Vu, C. C. Howe, and H. M. DeLisser
Bleomycin-induced pulmonary injury in mice deficient in SPARC
Am J Physiol Lung Cell Mol Physiol, October 1, 2000; 279(4): L743 - L750.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online